Elsevier

Advanced Drug Delivery Reviews

Volume 81, January 2015, Pages 62-74
Advanced Drug Delivery Reviews

Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics

https://doi.org/10.1016/j.addr.2014.10.029Get rights and content

Abstract

Hepatocellular carcinoma (HCC) remains one of the most lethal forms of cancer in the world. In this arena, utilities of microRNA (miRNA) as a sophisticated tool, in therapeutics and diagnostics, remains a prime focus among the leading researchers. It is well known that viral hepatitis, chronic alcoholism and metabolic syndrome are the prime causes of HCCs. Nevertheless, HCCs are usually diagnosed at late stages by using current serum biomarkers. Most epidemiological studies have found the survival rate in HCC cases to be relatively low. Therefore, development of effective noninvasive biomarkers for early detention of HCC and new strategies for HCC treatment remains a high priority research area on the shoulders of liver oncologists. Accumulating evidence in cancer diagnostics and therapeutics indicates that miRNAs involve in HCC progression, which may serve as sensitive biomarkers for detecting carcinogenesis and monitoring therapies of HCC. This review focuses on the role of miRNAs in the diagnostics and therapeutics of HCC.

Introduction

The liver is the largest internal organ in the human body. It is considered the “metabolic warehouse” and processes a vast number of macro- and micro-nutrients. Secreting bile is another important function of the liver which helps absorb nutrients. Metabolic or nutritional dysregulation can often lead to hepatocellular carcinoma (HCC), the most common form of liver cancer in the world. HCC is highly prevalent in certain areas of the world, especially in China [1]. HCCs are usually correlated with viral hepatitis infections, particularly hepatitis B or C, alcoholism or metabolic syndrome, such as fatty liver disease [2]. In the United States, hepatitis C is the main causative agent for initiating HCC. The survival rate of HCC is low and currently the incidence of HCC is on the rise every year. The all-stage survival rate is 16%, whereas the incidence rate increased by about 12% from 2006 to 2010 [3]. Developing diagnostic and prevention strategies relative to HCC has been an attractive area of research, however, HCC can only be diagnosed at a late stage by currently available serum biomarkers, such as α-fetoprotein (AFP), des-γ-carboxy prothrombin (DCP), and squamous cell carcinoma antigen-immunoglobulin M complexes (SCCA-IgM Cs) [4]. With the late diagnosis, the 5-year survival rate of HCC patients has been estimated to be very low.

MicroRNAs (miRNAs) are endogenous, evolutionarily conserved, noncoding RNAs that have been identified as post-transcriptional regulators of gene expression. Approximately 3% human genome codes for miRNA sequences, and the nucleus/cytoplasm are considered the prime intracellular locations of miRNA processing. It has also been determined that mature miRNAs are part of the RNA-induced silencing complex (RISC) which enables post-transcriptional control of gene expression. miRNAs negatively regulate gene expression, mainly through direct interaction with the 3′ untranslated region (3′-UTR) of corresponding target messenger RNAs (mRNAs). The cleavage of the target mRNA is induced only when miRNA–mRNA target sequence complementarity is established. In the case of partial complementarity, the binding of miRNAs leads to translational repression by inhibiting translation into proteins of the sequence. It is also established that each miRNA can target hundreds of mRNAs, and a particular mRNA transcript can be the target of several different miRNAs.

Numerous investigations have used miRNAs as biomarkers to facilitate the identification, characterization, and mechanistic understanding of chemically-induced carcinogenesis. Analysis of a plethora of research papers indicate that a large majority of protein-coding genes may be directly modulated by miRNAs. Identification of miRNA targets is important for our understanding the functions of miRNAs and their implications in disease development. Most human cancers show dual roles of miRNAs; they can function as oncogenes or tumor suppressor genes during tumor development and progression. Given the fact that, an estimated 30,640 new cases of liver cancer were expected to occur in the US during 2013, and more than 80% of these cases are HCCs, originating from hepatocytes, the need to explore the role of miRNAs in liver cancer appears to be critical. It is also noted that, despite numerous efforts to prevent cancer, an estimated 21,670 liver cancer deaths were observed in 2013. This alarming statistic has prompted intense investigation.

The very first report identifying the association between miRNAs and cancer was published in 2002. This report was based on the fact that miR-15-a and miR-16-1 are located on chromosome locus 13q14, a site frequently deleted in B-cell chronic lymphocytic leukemia cases. After this landmark report, numerous laboratories worldwide have identified aberrant expression of miRNAs in several other types of malignancies, e.g., breast cancer, brain cancer, colorectal carcinoma, HCC, lung cancer (commonly non-small cell lung cancer (NSCLC)), lymphomas, prostate cancer and thyroid cancer [5]. It is now clear that miRNAs play varied roles in different capacities in the carcinogenesis process, including metastasis, invasion, proliferation, cell cycle, and apoptosis. Mapping of miRNAs has disclosed that many of them are localized to fragile regions of the genome, and many miRNAs localized to these regions often have decreased expression in cancer cells. miRNAs target mRNAs and exhibit dual roles (both oncogenic and tumor suppressive) besides participating in a number of different cellular functions. Since normal and tumor cells as well as different tumor subtypes exhibit differential expression of miRNAs, these differences have been extrapolated as prognostic and predictive markers in cancer patients.

In this review, the pathophysiology of HCC, biogenesis of miRNAs and their regulation are discussed, keeping in focus potential application of miRNAs as diagnostic indicators and therapeutic agents. The possible modalities of miRNA delivery to treat HCC are also introduced.

Section snippets

Hepatocellular carcinoma

Hepatocellular carcinoma is the most common form of liver cancer and the third most common cause of cancer-related death. The annual global incidence of HCC is approximately 1 million cases, with a male to female ratio of approximately 4:1 [1]. Although the majority of HCC reported cases occur in Africa and Asia, the incidence of HCC has significantly increased in developed countries over the last few decades [6]. This increase is strongly correlated with increase in migration of chronic

miRNA biogenesis and regulation

miRNAs are small noncoding RNAs of about 20 to 24 nucleotides long which mainly function in posttranscriptional gene regulation [21]. As a regulator, miRNAs silence mRNAs thereby inhibiting the production of the prior coded proteins. Varieties of miRNAs are found in both plants and animals. It is estimated that at least 2000 human miRNAs have been discovered and they are found in almost all human cells. A number of studies associate miRNAs to numerous functions including cell proliferation,

Regulation of signaling network by miRNA association with HCC

miRNAs play a critical role in regulating the HCC tumorigenesis and metastasis signaling networks. Liu et al. found that miR-135a is up-regulated in HCC patients with portal vein tumor thrombus (PVTT) [26]. The same study also found that miR-135a is transcribed by forkhead box M1 (FOXM1) and directly targets suppressor 1 (MTSS1). miR-210 is another up-regulated miRNA in HCC. It was demonstrated that miR-210 can promote the migration and invasion of HCC cells by targeting vacuole membrane

miRNAs associated with HCC diagnosis

Future advances in HCC survival will likely depend in part on early diagnosis of HCC in high-risk patients. The miRNA expression profile could be used for diagnosis of cancers. Those miRNAs can be an individual [72], [73] or a panel [74], [75]. Actually, identification of noninvasive serum biomarkers for the diagnosis of HCC has been under investigation since 1980s. A literature review compared the accuracy of AFP, DCP, and SCCA-IgM Cs in the early diagnosis and in the prognosis of HCC [4]. It

Conclusions and future remarks

In the new millennia, evolving technological applications and novel biomarkers together with molecular biology have clearly paved the way for clinical oncologists to choose infinite therapeutic modalities for a staggering number of cancers. In the future, this period may be recognized as “the golden age of chemotherapy” because of landmark discoveries in cancer detection, diagnosis, and treatments. It is now common that clinical oncologists prefer more personalized treatment strategies to treat

References (118)

  • W.P. Tsang et al.

    Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells

    J. Nutr. Biochem.

    (2010)
  • S. Shimizu et al.

    The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma

    J. Hepatol.

    (2010)
  • K. Polyak et al.

    Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

    Cell

    (1994)
  • C. Xu et al.

    MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells

    Eur. J. Cancer

    (2010)
  • S. Kim et al.

    MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2)

    J. Biol. Chem.

    (2008)
  • F. Meng et al.

    MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer

    Gastroenterology

    (2007)
  • Y. Wang et al.

    MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling

    Biochem. Biophys. Res. Commun.

    (2014)
  • P.K. Santhekadur et al.

    Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221

    J. Biol. Chem.

    (2012)
  • T.-C. Shih et al.

    MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma

    J. Hepatol.

    (2012)
  • G. Alpini et al.

    Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer

    J. Hepatol.

    (2011)
  • A. Budhu et al.

    Transforming the microenvironment: a trick of the metastatic cancer cell

    Cancer Cell

    (2012)
  • P. Yang et al.

    TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma

    Cancer Cell

    (2012)
  • K.M. Foss et al.

    miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer

    J. Thorac. Oncol.

    (2011)
  • R. Liu et al.

    A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis

    Eur. J. Cancer

    (2011)
  • R. Rosell et al.

    Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer

    Clin. Lung Cancer

    (2009)
  • C. Morrison et al.

    A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver

    Mod. Pathol.

    (2002)
  • A. Karabork et al.

    The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma

    Pathol. Res. Pract.

    (2010)
  • I. Barshack et al.

    Differential diagnosis of hepatocellular carcinoma from metastatic tumors in the liver using microRNA expression

    Int. J. Biochem. Cell Biol.

    (2010)
  • C.C.L. Wong et al.

    The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2

    Gastroenterology

    (2011)
  • J. Kota et al.

    Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model

    Cell

    (2009)
  • R. Dhanasekaran et al.

    Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics

    Hepat. Med.

    (2012)
  • L.S. Goodman

    Goodman and Gilman's The Pharmacological Basis of Therapeutics

    (1990)
  • R. Siegel et al.

    Cancer statistics, 2014

    CA Cancer J. Clin.

    (2014)
  • G. Bertino et al.

    Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma

    Minerva Med.

    (2011)
  • G.A. Calin et al.

    MicroRNA signatures in human cancers

    Nat. Rev. Cancer

    (2006)
  • H. Neumann et al.

    Harrison's Principles of Internal Medicine

    (2011)
  • H.-I. Yang et al.

    Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

    J. Clin. Oncol.

    (2010)
  • A. Forner et al.

    Current strategy for staging and treatment: the BCLC update and future prospects

  • A.S. Fauci

    Harrison's Principles of Internal Medicine

    (2008)
  • C.G. Child et al.

    Surgery and portal hypertension

    Major Probl. Clin. Surg.

    (1964)
  • J.H. Kwon et al.

    Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer

    BMC Cancer

    (2010)
  • M.E. Facciuto et al.

    Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response

    J. Surg. Oncol.

    (2012)
  • R. Salem et al.

    Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

    Gastroenterology

    (2011)
  • P. Hilgard et al.

    Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival

    Hepatology

    (2010)
  • K. Chen et al.

    The evolution of gene regulation by transcription factors and microRNAs

    Nat. Rev. Genet.

    (2007)
  • K.R. Cordes et al.

    MicroRNA regulation of cardiovascular development

    Circ. Res.

    (2009)
  • B.L. Davidson et al.

    Current prospects for RNA interference-based therapies

    Nat. Rev. Genet.

    (2011)
  • J.L. Umbach et al.

    The role of RNAi and microRNAs in animal virus replication and antiviral immunity

    Genes Dev.

    (2009)
  • Q. Ying et al.

    Hypoxia‐inducible microRNA‐210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma

    Hepatology

    (2011)
  • L. Gramantieri et al.

    MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality

    Clin. Cancer Res.

    (2009)
  • Cited by (188)

    View all citing articles on Scopus

    This review is part of the Advanced Drug Delivery Reviews theme issue on “miRNAs as targets for cancer treatment: Therapeutics design and delivery”.

    View full text